Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS

The aim of the study was to examine the benefits of the joint use of repeat FNA (rFNA) and EU-TIRADS in category III nodules in relation to the kind of atypia: nuclear vs. architectural (denoted by AUS and FLUS respectively). The study included 127 AUS and 1739 FLUS nodules with a known category of...

Full description

Bibliographic Details
Main Authors: Dorota Słowińska-Klencka, Mariusz Klencki, Joanna Duda-Szymańska, Bożena Popowicz
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/18/4489
_version_ 1797490257752489984
author Dorota Słowińska-Klencka
Mariusz Klencki
Joanna Duda-Szymańska
Bożena Popowicz
author_facet Dorota Słowińska-Klencka
Mariusz Klencki
Joanna Duda-Szymańska
Bożena Popowicz
author_sort Dorota Słowińska-Klencka
collection DOAJ
description The aim of the study was to examine the benefits of the joint use of repeat FNA (rFNA) and EU-TIRADS in category III nodules in relation to the kind of atypia: nuclear vs. architectural (denoted by AUS and FLUS respectively). The study included 127 AUS and 1739 FLUS nodules with a known category of EU-TIRADS. Repeat FNA was performed in 82 AUS and 934 FLUS nodules of which 57 and 515 were excised, respectively. AUS nodules had higher malignancy risk than FLUS nodules. EU-TIRADS showed higher accuracy for AUS nodules, the opposite to rFNA, that had higher accuracy for FLUS nodules. The combined criterion for AUS nodules (at least rFNA-V or EU-TIRADS-4) maximized sensitivity (92.3%) with acceptable specificity (70.0%); OR: 28.0. In the case of FLUS nodules, the combined criterion (rFNA-V or EU-TIRADS-5) maximized specificity (95.2%) with 57.7% sensitivity and a low percentage (13.9%) of positive nodules, OR: 27.0. In both types of nodules, the low risk category in EU-TIRADS and benign result of rFNA excluded cancer. Concluding, category III nodules with and without nuclear atypia differ in their risk of malignancy and, consequently, diagnostic criteria adopted for the evaluation of these nodules with rFNA and EU-TIRADS should be specific to AUS and FLUS nodules.
first_indexed 2024-03-10T00:29:25Z
format Article
id doaj.art-492f530f6e134227a6c2927f66897a0d
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T00:29:25Z
publishDate 2022-09-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-492f530f6e134227a6c2927f66897a0d2023-11-23T15:28:09ZengMDPI AGCancers2072-66942022-09-011418448910.3390/cancers14184489Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADSDorota Słowińska-Klencka0Mariusz Klencki1Joanna Duda-Szymańska2Bożena Popowicz3Department of Morphometry of Endocrine Glands, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandDepartment of Morphometry of Endocrine Glands, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandDepartment of Pathomorphology, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandDepartment of Morphometry of Endocrine Glands, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandThe aim of the study was to examine the benefits of the joint use of repeat FNA (rFNA) and EU-TIRADS in category III nodules in relation to the kind of atypia: nuclear vs. architectural (denoted by AUS and FLUS respectively). The study included 127 AUS and 1739 FLUS nodules with a known category of EU-TIRADS. Repeat FNA was performed in 82 AUS and 934 FLUS nodules of which 57 and 515 were excised, respectively. AUS nodules had higher malignancy risk than FLUS nodules. EU-TIRADS showed higher accuracy for AUS nodules, the opposite to rFNA, that had higher accuracy for FLUS nodules. The combined criterion for AUS nodules (at least rFNA-V or EU-TIRADS-4) maximized sensitivity (92.3%) with acceptable specificity (70.0%); OR: 28.0. In the case of FLUS nodules, the combined criterion (rFNA-V or EU-TIRADS-5) maximized specificity (95.2%) with 57.7% sensitivity and a low percentage (13.9%) of positive nodules, OR: 27.0. In both types of nodules, the low risk category in EU-TIRADS and benign result of rFNA excluded cancer. Concluding, category III nodules with and without nuclear atypia differ in their risk of malignancy and, consequently, diagnostic criteria adopted for the evaluation of these nodules with rFNA and EU-TIRADS should be specific to AUS and FLUS nodules.https://www.mdpi.com/2072-6694/14/18/4489thyroidcancerFNABethesda systemAUSFLUS
spellingShingle Dorota Słowińska-Klencka
Mariusz Klencki
Joanna Duda-Szymańska
Bożena Popowicz
Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
Cancers
thyroid
cancer
FNA
Bethesda system
AUS
FLUS
title Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
title_full Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
title_fullStr Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
title_full_unstemmed Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
title_short Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS
title_sort optimization of the management of category iii thyroid nodules using repeat fna and tirads
topic thyroid
cancer
FNA
Bethesda system
AUS
FLUS
url https://www.mdpi.com/2072-6694/14/18/4489
work_keys_str_mv AT dorotasłowinskaklencka optimizationofthemanagementofcategoryiiithyroidnodulesusingrepeatfnaandtirads
AT mariuszklencki optimizationofthemanagementofcategoryiiithyroidnodulesusingrepeatfnaandtirads
AT joannadudaszymanska optimizationofthemanagementofcategoryiiithyroidnodulesusingrepeatfnaandtirads
AT bozenapopowicz optimizationofthemanagementofcategoryiiithyroidnodulesusingrepeatfnaandtirads